Tahiri Maha, Tressol Jean C, Arnaud Josiane, Bornet Francis R J, Bouteloup-Demange Corinne, Feillet-Coudray Christine, Brandolini Marion, Ducros Véronique, Pépin Denise, Brouns Fred, Roussel Anne M, Rayssiguier Yves, Coudray Charles
Centre de Recherche en Nutrition Humaine d'Auvergne, Unité Maladies Métaboliques et Micronutriments, Centre de Recherche INRA Clermont-Ferrand/Theix, Saint Genès Champanelle, France.
Am J Clin Nutr. 2003 Feb;77(2):449-57. doi: 10.1093/ajcn/77.2.449.
An enhancing effect of short-chain fructooligosaccharides (scFOSs) on intestinal calcium absorption has been shown in animals and in some short-term human studies. However, the long-term effect of scFOSs on calcium absorption in humans is still unknown.
We investigated the long-term effect of a moderate daily dose (10 g) of scFOSs on intestinal calcium absorption in postmenopausal women.
In a randomized, double-blind crossover protocol, 12 healthy, postmenopausal women received scFOSs or placebo for 5 wk. The treatments were separated by a 3-wk washout period. Subjects orally received (44)Ca (stable isotope) and a fecal marker. Feces were collected after the isotope intake for 5-7 d to measure unabsorbed isotope. Calcium-status indexes, calciotropic hormones, and bone turnover were also assessed.
Mean (+/-SD) intestinal calcium absorption with scFOS treatment was not significantly different from that with placebo treatment (35.63 +/- 9.40% and 36.55 +/- 8.48%, respectively). However, a tendency for calcium absorption to be higher with scFOS treatment than with placebo treatment was observed in women who had been going through menopause for >6 y.
scFOSs do not modify intestinal calcium absorption in postmenopausal women who do not receive hormonal replacement therapy. The results from a subgroup of women who had been going through menopause for >6 y (n = 6) suggest that scFOSs may influence calcium absorption in the late postmenopausal phase. The small number of subjects and the related P value warrant verification and further investigation with women in late menopause only.
短链低聚果糖（scFOSs）对肠道钙吸收的增强作用已在动物实验和一些短期人体研究中得到证实。然而，scFOSs对人体钙吸收的长期影响仍不清楚。
我们研究了每日中等剂量（10 g）的scFOSs对绝经后妇女肠道钙吸收的长期影响。
采用随机、双盲交叉试验方案，12名健康绝经后妇女接受scFOSs或安慰剂治疗5周。两次治疗之间有3周的洗脱期。受试者口服（44）Ca（稳定同位素）和一种粪便标记物。同位素摄入后5 - 7天收集粪便，以测量未吸收的同位素。还评估了钙状态指标、促钙激素和骨转换情况。
scFOSs治疗组的平均（±标准差）肠道钙吸收率与安慰剂治疗组无显著差异（分别为35.63±9.40%和36.55±8.48%）。然而，在绝经超过6年的女性中，观察到scFOSs治疗组的钙吸收率有高于安慰剂治疗组的趋势。
scFOSs对未接受激素替代疗法的绝经后妇女的肠道钙吸收没有影响。绝经超过6年的女性亚组（n = 6）的结果表明，scFOSs可能影响绝经后期的钙吸收。受试者数量较少及相关P值需要仅在绝经后期女性中进行验证和进一步研究。
